Document is current
Any future updates will be listed below
-
Authors
McDonald, Hannah G.
Kennedy, Andrew
Solomon, Angelica L.
Williams, Chelsey M.
Reagan, Anna M.
Cassim, Emily
Harper, Megan
Burke, Erin
Armstrong, Terra
Gosky, Michael
Cavnar, Michael
Pandalai, Prakash K.
Barry-Hundeyin, Mautin
Patel, Reema
Nutalapati, Snigdha
Moss, Jessica
Hull, Pamela C.
Kolesar, Jill
Pickarski, Justine C.
Kim, Joseph
-
Funding
Funding for this research was provided by:
NIH (NIH T32CA60003)
- License Information
-
More Information
Article History
Received: 20 May 2024
Accepted: 25 July 2024
First Online: 12 August 2024
DISCLOSURE
: Jill Kolesar has received grant support, paid to her institution, from Lilly@LOXO and ArtemiLife, and is a founder of and has ownership in Helix Diagnostics and VesiCure Technologies. Pamela Hull has received grants from the Merck Foundation: Comprehensive Connected Cancer Care (C4) [multi-PI]; the American Cancer Society: Enhancing Patient Navigation at the University of Kentucky Markey Cancer Center (multi-PI); and Eli Lilly and Company: PRiMAL: Pragmatic Randomized Clinical Trial Comparing Molecular Tumor Board-Assisted Care to Usual Care (co-investigator). Pamela Hull has received personal fees from St. Jude Children’s Hospital and Cancer Center, Moffitt Cancer Center, AdventHealth, and Kentucky Rural Health Association. Hannah G. McDonald, Andrew Kennedy, Angelica L. Solomon, Chelsey M. Williams, Anna M. Reagan, Emily Cassim, Megan Harper, Erin Burke, Terra Armstrong, Michael Gosky, Michael Cavnar, Prakash K. Pandalai, Mautin Barry-Hundeyin, Reema Patel, Snigdha Nutalapati, Jessica Moss, Justine C. Pickarski, and Joseph Kim have no conflicts of interest to declare that may be relevant to the contents of this article.
